30 Minutes. 8 Questions.
Asembia, April 28 to 30
Virtual through May 2026
Or reply directly to the person who sent you this link.
Your Research Leads
AI Advisory for Specialty Pharma | genflare.ai
Specialty Pharma Commercial Intelligence, 2026
Independent research with 25 to 30 senior commercial leaders across specialty pharma, mapping the real capability gaps in commercial operations as AI reshapes the function.
genflare.ai | AI Advisory for Specialty Pharma | April 2026
Specialty pharma is the fastest-growing segment in the industry. AI investment is accelerating. But the gap between spending and real commercial impact keeps widening.
Most research on AI in pharma is theoretical. It tells you what the industry could do. It rarely tells you what commercial teams are actually experiencing on the ground.
Analyst reports size the market. They don't capture the operational reality inside commercial organizations that are trying to get real work done with AI.
Consulting firms publish readiness models and maturity curves. But commercial operators don't need another framework. They need to know what's actually working and what's not.
Current research tells you what to think about AI. It doesn't tell you what to do about it. The gap between strategy and execution is exactly where teams are stuck.
Not the CIOs. Not the data scientists. The VPs of Market Access, Patient Services, and Brand who own the P&L and live with the consequences. The people navigating payer dynamics, enrollment friction, field team adoption, and patient drop-off every day.
Structured, execution-focused independent research with senior commercial leaders across specialty pharma. Findings published as the Genflare 2026 AI Signal Report in June.
VPs and above across market access, patient services, brand, and commercial operations at specialty pharma companies.
AI adoption, capability gaps, partner expectations, budget readiness. Structured enough to quantify. Open enough for nuance.
Sessions at Asembia (April 28 to 30) and virtual through May. 30 minutes, scheduled around you.
The first primary research built from the commercial operators themselves.
Your perspective shapes an industry artifact that will be read by commercial leaders across specialty pharma. This is your voice in the conversation.
Every participant receives the complete synthesized findings before public release. What your peers said, anonymized and unfiltered.
In your name, to a cause of your choice. A small gesture of thanks for your time and expertise.
Sessions at Asembia and virtually through May.
Or reply directly to the person who sent you this link.
AI Advisory for Specialty Pharma | genflare.ai